When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Personality disorders

最后审阅: 17 Jan 2026
最后更新: 02 Apr 2025

小结

定义

病史和体格检查

关键诊断因素

  • paranoia
  • odd thinking
  • restricted range of emotions
  • anger and irritability
  • excessive emotionality and unstable mood states
  • anxiety and tension
  • impulsive behaviors
  • grandiosity
  • evidence of self harm (e.g., scars, burns)
完整详情

危险因素

  • history of abuse
  • family history of schizophrenia
  • family history of borderline personality disorder (BPD)
  • negative parenting interactions
  • emotional/disruptive disorder in childhood
完整详情

诊断性检查

首要检查

  • clinical interview
完整详情

需考虑的检查

  • suicide risk screening questions
  • Standardized Assessment of Personality-Abbreviated Scale (SAPAS)
  • Millon Clinical Multiaxial Inventory-III (MCMI-III)
  • Structured Clinical Interview for DSM-5-TR Alternative Model for Personality Disorders Version (SCID-5-AMPD)
  • Structured Clinical Interview for DSM-5-TR Personality Disorders
  • MRI/CT scan of brain
  • urine drug screen
  • The Primary Care Evaluation of Mental Disorders (PRIME-MD)
  • Patient Health Questionnaire-9 (PHQ-9)
  • Mood Disorder Questionnaire
  • Generalized Anxiety Disorder-7 (GAD-7) and GAD-2
完整详情

治疗流程

急症处理

at risk for harming self or others, or unable to attend to basic self-needs

持续性治疗

cluster A (odd/eccentric): non-life-threatening, not pregnant or breastfeeding

cluster B (dramatic): non-life-threatening, not pregnant or breastfeeding

cluster C (anxious): non-life-threatening, not pregnant or breastfeeding

multiple features of different personality disorders: non-life-threatening, not pregnant or breastfeeding

any cluster or multiple features of different personality disorders: non-life-threatening, pregnant or breastfeeding

撰稿人

作者

Michael J. Schrift, DO, MA
Michael J. Schrift

Professor

Department of Psychiatry and Behavioral Sciences

University of Washington

Seattle

WA

利益声明

MJS declares he has no competing interests.

鸣谢

Dr Michael J. Schrift would like to gratefully acknowledge Dr Crystal T. Clark, and the late Dr Maria Devens, previous contributors to this topic. He would also like to acknowledge Dr Eric Gausche, who contributed the psychopharmacology sections for the initial version, and Dr Richard Stringham, who reviewed and approved information on the use of imaging and laboratory tests in the diagnosis section in the initial version. MD was an author of references cited in this topic. CTC, EG, and RS declare that they have no competing interests.

同行评议者

Anthony W. Bateman, FRCPsych

Consultant Psychiatrist and Visiting Professor

Halliwick Psychotherapy Unit

St Ann’s Hospital

London

UK

利益声明

AWB declares that he has a bias towards the use of mentalization in the treatment of personality disorder.

Robin L. Kissell, MD

Director

Borderline Personality Disorder Initiative

Semel Institute

UCLA

Los Angeles

CA

Declarações

RLK declares that she has no competing interests.

Justin Trevino, MD

Medical Director

Opioid Treatment Program

Dayton Veterans Affairs Medical Center

Dayton

OH

Disclosures

JT declares that he has no competing interests.

Dietmar Winkler, MD

Department of Psychiatry and Psychotherapy

Medical University of Vienna

Vienna

Austria

Disclosures

DW has received lecture fees from CSC Pharmaceuticals, GlaxoSmithKline, and Pfizer, and has served as a consultant for GlaxoSmithKline.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed, text revision (DSM-5-TR). Washington, DC: American Psychiatric Association; 2022.Full text

Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiatry. 2024 Nov 1;181(11):1024-8. Abstract

Storebø OJ, Stoffers-Winterling JM, Völlm BA, et al. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev. 2020 May 4;5:CD012955.Full text  Abstract

Cristea IA, Gentili C, Cotet CD, et al. Efficacy of psychotherapies for borderline personality disorder: a systematic review and meta-analysis. JAMA Psychiatry. 2017 Apr 1;74(4):319-28.Full text  Abstract

Abbass AA, Kisely SR, Town JM, et al. Short-term psychodynamic psychotherapies for common mental disorders. Cochrane Database Syst Rev. 2014 Jul 1;(7):CD004687.Full text  Abstract

Herpertz SC, Zanarini M, Schulz CS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders. World J Biol Psychiatry. 2007;8(4):212-44.Full text  Abstract

Reference articles

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
  • Differentials

    • Mood disorders
    • Psychotic disorders
    • Anxiety disorders
    More Differentials
  • Guidelines

    • Treatment of patients with borderline personality disorder
    • Antisocial personality disorder: prevention and management
    More Guidelines
  • Patient information

    Personality disorders: what are they?

    Personality disorders: what are the treatment options?

    More Patient information
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer